HeyJaredThe Biotech Investor
Welcome to The Biotech Investor 🧬 Your premier resource for insights into the rapidly evolving biotech sector. Focused on emerging small to medium-sized biotech companies, we delve into the groundbreaking therapies and medications they are poised to introduce 💊.
- Indexed videos, last 90 days
- 9
- Latest publication
- Sep 1, 2026
- Audience
- ~11.8K subscribers
- Earliest in this view
- Jul 9, 2026
Latest videos
$CUE Deep Dive: Genius Reinvention or Last Resort? | Cue Biopharma (opens the original)
Read excerpt
Five months ago, Cue Biopharma was a cancer T-cell company. Today it's an allergy company with a new CEO, a new lead drug — and about $17M in the bank with a "going concern" warning in its own filing. Everything now rides on one Phase 2 readout in chronic spontaneous urticaria, expected by the end of September. In this deep dive I break down the whole story: the disease and the market gap (over half of treated patients still aren't controlled), how CUE-221's "sponge + faucet" mechanism differs f
Biotech Investing Research Platform (opens the original)
Read excerpt
Sign up for a free trial at www.thebiotechinvestor.co
The two golden rules of investing 'Don't lose money' and 'Don't forget rule number one' 1 (opens the original)
Read excerpt
The two golden rules of investing 'Don't lose money' and 'Don't forget rule number one' 1 Watch the full Episode: https://youtu.be/CzWvizCiZ2Y
A message of faith and trust If you could go back to your lowest point, what advice would you give (opens the original)
Read excerpt
A message of faith and trust: If you could go back to your lowest point, what advice would you give? #biotechnology #biotech Watch the full Episode: https://youtu.be/CzWvizCiZ2Y
Why you should never double down on a losing bet and the importance of letting a position play out. (opens the original)
Read excerpt
Why you should never double down on a losing bet and the importance of letting a position play out. #biotechnology #biotech Watch the full Episode: https://youtu.be/CzWvizCiZ2Y
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
~11.8K subscribers
Measured Sep 19, 2026
Source's subscribers, not the number who saw an individual piece.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.